Impact Factor
3.69
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.96
952 total citations
h5-index
31
h5 depth signal
Cited share
78.5%
197 of 251
Total citations
952
Citation footprint
Metric signal
3.83
External metric anchor
Self-citation
0.6%
6 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
India
356
China
195
United States
140
Italy
127
Saudi Arabia
89
Citing Fields of Research
Neurodegenerative Disorders
535
Neurosciences
227
Brain Neurological Disorders
137
Psychiatry
103
Phytochemicals
82
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,304
Articles tracked across the journal lifetime
Indexed publication set
251
197 cited publications
Last 12 months
185
15.4 publications/month
Open access share
2.2%
4 OA publications in the last year
Leading citing country
India
356 citing publications
Leading citing field
Neurodegenerative Disorders
535 citing publications
Latest tracked publication
14 October 2026
10 recent records available
Coverage & Indexing History
v5n1, Feb. 2006-
v5n1, Feb. 2006-
Research Focus & Classification
Indexed Subjects
Neurodegenerative Disorders
Broad Categories
Drug Therapy
Neurology
Neurodegenerative Disorders
Neurosciences
Brain Neurological Disorders
Musculoskeletal Disorders
Neuromuscular Disorders
Neurodevelopmental Disorders
MeSH Descriptors
Central Nervous System Diseases
Drug Delivery Systems
Drug Design
Nervous System Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.2174/0118715273491538261009064612
Open DOI
Mechanistic Evaluation of Psilocybin in Neurodegenerative Disorders: Relevance of 5-HT2A Receptors and Downstream Pathways
More than fifty million individuals worldwide are experiencing neurodegenerative disorders, which include Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, Huntington’s disease, multiple sclerosis, and frontotempor...
02
DOI 10.2174/0118715273531307261012100737
Open DOI
From Hypothesis to Clinical Validation: A Bibliometric Mapping of Immunotherapy for Neurodegenerative Proteinopathies (2000–2025)
Introduction/Objective: For twenty-five years, despite persistent challenges, the field of neurodegenerative disease has remained committed to a single hypothesis: targeting the immune system directly against misfolded proteins accumulat...
03
DOI 10.2174/0118715273467000261004044651
Open DOI
Overview of the Mechanistic Potential of Serotonin Reuptake Transporters in Depression
Depression is considered to be one of the most common psychiatric disorders that affect millions of people, despite a large amount of unrecorded data. This disorder has been associated with feelings of hopelessness, sleep disturbances, a...
04
DOI 10.2174/0118715273492918261001111401
Open DOI
Unraveling Shared Molecular Mechanisms in Alzheimer's, Parkinson's, and Neuropathic Pain: Targeting p38 MAPK and Wnt/β-Catenin Pathways
Neurodegenerative disorders, including Alzheimer's Disease (AD), Parkinson's Disease (PD), and Neuropathic Pain (NP), share overlapping molecular and cellular mechanisms that contribute to progressive neuronal dysfunction, neuroinflammat...
05
DOI 10.2174/0118715273467333261002070852
Open DOI
Aging-driven Mechanisms Underlying Parkinson’s Disease Pathogenesis: Molecular, Cellular, and Systemic Perspectives
Aging is a major risk factor for Parkinson's Disease (PD) and is linked to various biological processes at the molecular, cellular, and systemic levels. At the molecular level, aging-related oxidative stress, mitochondrial dysfunction, g...
06
DOI 10.2174/0118715273472775260929093840
Open DOI
Prolactin and Neuroendocrine Regulation in Brain Injury: Mechanisms of Adaptive Plasticity and Therapy Strategies
Background: Acquired Brain Injuries (ABIs) represent a significant worldwide health challenge, with few specific medicines available to enhance recovery. Growing data underscores neuroendocrine dysfunction, especially with prolactin as a...
07
DOI 10.2174/0118715273503588260911101820
Open DOI
Exploring Progressive Multiple Sclerosis and the Therapeutic Potential of BTK Inhibitors Based on EBV-driven B Cell–microglia Interactions
Progressive Multiple Sclerosis (PMS) remains a major cause of irreversible disability in Multiple Sclerosis (MS), yet current disease-modifying therapies incompletely address the compartmentalized Central Nervous System (CNS) inflammatio...
08
DOI 10.2174/0118715273459828260925063553
Open DOI
Molecular Footprints of Diabetic Peripheral Neuropathy: Investigating Transcriptional Modulation of Sphingolipid Metabolism, Myelin-specific Genes and Neurotrophic Factors Under Elevated Glucose and Harnessing Therapeutic Potential of DHA and ALA
Background: Research has shown that disturbances in sphingolipid metabolic homeostasis are significant contributors to Diabetic Peripheral Neuropathy (DPN). Ceramides and their metabolites are cell signaling molecules involved in islet c...
09
DOI 10.2174/0118715273459017260922073618
Open DOI
Neuroinflammation and Autophagy in Neurodegeneration: Cellular Mechanisms and Therapeutic Strategies
Neurodegenerative diseases, including Huntington’s disease, Parkinson’s disease, Alzheimer’s disease, and Amyotrophic Lateral Sclerosis (ALS), are characterized by progressive neuronal dysfunction and loss, often accompanied by toxic pro...
10
DOI 10.2174/0118715273502075260910113533
Open DOI
Resveratrol's Therapeutic Role in Sepsis-Associated Encephalopathy
Introduction/Objective: Sepsis-Associated Encephalopathy (SAE) represents a lifethreatening complication of sepsis, whose pathogenesis is driven by intestinal dysbiosis through bidirectional gut–brain axis signaling. Resveratrol, a neuro...
Bibliographical & Catalog Notes
Title from cover.
Also issued online.